Showing results (101-110 of 118) with videos related to
Sort By:
Pageof 12
Nature Medicine|July 16, 2025
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Jianwei Yang, Yuping Sun, et al.The Lancet. Respiratory Medicine|December 15, 2023
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trialMengzhao Wang, Yun Fan, Meili Sun, et al.The Lancet. Oncology|June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trialCaicun Zhou, Ziping Wang, Meili Sun, et al.Advances in Therapy|September 4, 2024
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III StudyYing Cheng, Zhanyu Pan, Lin Wu, et al.Nature Medicine|March 28, 2026
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trialByoung Chul Cho, Rama Balaraman, Hua-Jun Chen, et al.Cancer Communications (London, England)|April 2, 2026
Rezivertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR StudySheng Yang, Yanqiu Zhao, Meili Sun, et al.The Lancet. Respiratory Medicine|February 3, 2024
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trialHua Zhong, Shengjie Sun, Jianhua Chen, et al.Signal Transduction and Targeted Therapy|February 27, 2025
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trialDan-Yun Ruan, Wen-Wen Huang, Yongsheng Li, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b StudyYuankai Shi, Shiman Wu, Ke Wang, et al.Cell Reports. Medicine|May 7, 2025
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutationYan Xu, James Chih-Hsin Yang, Yanqiu Zhao, et al.Pageof 12